Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT

Rationale: In the IMPACT (Informing the Pathway of COPD Treatment) trial, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy reduced exacerbation risk versus FF/VI and UMEC/VI and mortality risk versus UMEC/VI. However, pneumonia incidence was higher in the inhale...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Am Thorac Soc
Hlavní autoři: Dransfield, Mark T., Crim, Courtney, Criner, Gerard J., Day, Nicola C., Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, LaFon, David, Lipson, David A., Lomas, David A., Martin, Neil, Martinez, Fernando J., Singh, Dave, Wise, Robert A., Lange, Peter
Médium: Artigo
Jazyk:Inglês
Vydáno: American Thoracic Society 2021
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8086537/
https://ncbi.nlm.nih.gov/pubmed/33108212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/AnnalsATS.202002-096OC
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky